Proteins and Peptides
19 September 2014
Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes19 September 2014
Paediatric Patients with Hypophosphatasia Receiving Investigational Asfotase Alfa Had Sustained Improvements in Growth and Physical Function18 September 2014
Ryzodeg® provides successful glycaemic control with fewer injections than a basal-bolus regimen18 September 2014
biOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation18 September 2014
SWOG To Resume Clinical Trial Of Halozyme’s PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer16 September 2014
Mylan Commences Phase III Clinical Trials for its Generic Version of Advair Diskus® and Insulin Analog to Lantus16 September 2014
CSL Behring Announces Last Patient Treated in Phase III Study of Fibrinogen Concentrate to Control Bleeding During Aortic Aneurysm Surgery16 September 2014
Thrasos Announces Successful Formal Interim Analysis and Clinical Update for Phase 2 Study of THR-184 for Acute Kidney Injury15 September 2014
Ultragenyx Announces Positive Results From a Long-Term Phase 1/2 Study of KRN23 in Adult Patients With X-Linked Hypophosphatemia15 September 2014
FDA Approves Baxter’s RIXUBIS [Coagulation Factor IX (Recombinant)] for Treatment of Children with Hemophilia B13 September 2014
FDA Advisory Committee Recommends Approval of Natpara® for Long-Term Treatment of Hypoparathyroidism13 September 2014
Novartis demonstrates leadership in ophthalmology with new products and over 40 abstracts at EURETINA12 September 2014
Saxenda® for the treatment of obesity receives positive 14-1 vote in favor of approval from FDA Advisory Committee11 September 2014
PLEGRIDY™ (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance of Efficacy and Safety in Multiple Sclerosis Patients10 September 2014
European Commission grants Lilly and Boehringer Ingelheim’s insulin glargine product marketing authorisation in Europe10 September 2014
EMD Serono Presents New Data on Rebif ® (Interferon beta-1a) and Multiple Sclerosis Pipeline at Joint ACTRIMS-ECTRIMS Meeting in Boston9 September 2014
Mimetogen Pharmaceuticals Announces Topline Results of Its Second Clinical Study with MIM-D3 for the Treatment of Dry Eye Syndrome9 September 2014
C3 Jian Completes Phase 2 Clinical Trial of Anti-Cavity Drug8 September 2014
Synthetic Biologics Highlights New Data from C. difficile Program Presented at the 54th ICAAC4 September 2014
Lilly’s Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus® in Phase III Trials in Patients with Type 1 Diabetes3 September 2014
Ultragenyx Announces Positive Interim Data From Phase 1/2 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis 73 September 2014
Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and Biomarker Efficacy SignalsNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe